Randomized double-blind parallel controlled clinical trail of Chenpi enzyme in the treatment of hyperlipidemia
- Conditions
- Hyperlipidemia
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Patients aged 18-75 years;
2. Patients with dyslipidemia;
3. The cardiovascular risk was assessed as low risk patients;
4. Those who voluntarily participate in the research and sign the informed consent.
1. Patients who were taking antilipidemic drugs within 3 months before inclusion;
2. Patients with nephrotic syndrome, hypothyroidism, renal failure, liver disease and systemic lupus erythematosus;
3. Patients with myeloma, glycogen accumulation, fatty atrophy, acute porphyria and polycystic ovary syndrome;
4. Patients taking drugs related to lipid metabolism, such as diuretics, beta blockers, glucocorticoids, metformin, insulin and contraceptives;
5. Patients whose systolic blood pressure is still >= 180mmhg or diastolic blood pressure is still >= 110mhg after treatment;
6. After oral drug treatment, the blood glucose is still >= 11.1mmol/L Of patients;
7. TG >= 5.65mmol/L Those who;
8. Patients with heart, liver, kidney, hematopoietic system, immune system and other systemic serious diseases;
9. Pregnant or lactating women or those who plan to be pregnant during the trial period or their spouses plan to be pregnant;
10. Patients with allergic constitution, possible allergy to the drug or psychosis;
11. Other patients who cannot cooperate for a long time.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TC;HDL-C;LDL-C;TG;
- Secondary Outcome Measures
Name Time Method A;GLU;BMI;The proportion of blood lipid components meet the standard;CRP;